Larotrectinib is finally launched in China. How can I buy it cheaply?

Larotrectinib is an innovative anti-cancer drug that belongs to the category of targeted therapy. It is unique in that it effectively inhibits the activity of the abnormal TRK protein in cancer patients with TRK (neuroectodermal tumor) gene fusions. TRKGene fusion is a rare but present genetic abnormality in a variety of tumors that causes the production of abnormal TRK proteins, driving the proliferation of cancer cells.

Larotrectinib has been launched in China and has not yet been included in medical insurance. Since it has not been launched in China for a long time, it may be difficult to purchase it in hospitals. For specific conditions, it is recommended to consult the local hospital pharmacy. In foreign markets, larotinib has two options: original drug and generic drug. Original drugs include the German version, the American version, the European version and the Hong Kong version, and the price is about 10,000 to 20,000 yuan. In comparison, generic drugs are much cheaper. There are Lao and Bangladeshi versions of generic drugs, and the price is around two to three thousand. It is worth noting that the ingredients of original drugs and generic drugs are basically the same.

Larotinib is administered as an oral drug and interferes with the growth and division process of cancer cells by targeting the activity of abnormalTRK proteins. This treatment method emphasizes the concept of personalized treatment. Patients need to undergo genetic testing before use to determine whether there is TRK gene fusion to ensure the precise application of the drug.

Main indications include pediatric soft tissue sarcomas and adultsTRK gene fusion-positive solid tumors. For children with soft tissue sarcoma, larotrectinib has shown significant efficacy in clinical trials and has a positive impact on patients' survival and quality of life. At the same time, larotrectinib has also demonstrated significant therapeutic effects in adult patients, especially those with solid tumors harboring TRK gene fusions.

xa0